TNFSF10 and fibrosarcoma: Combination of sorafenib, an inhibitor of multicellular TRAIL resistance, with the penetrating peptide iRGD significantly enhanced the anticancer effect of the recombinant protein izTRAIL in HT-1080 human fibrosarcoma grafts in nude mice.